In response to this robust performance, Bausch + Lomb raised its full-year 2024 guidance. The company now projects revenue in the range of $4.700 billion to $4.800 billion, representing a constant ...

Anyone seeking to report adverse effects should contact Bausch + Lomb at 800-338-2020, option 1, or submit a report to the FDA’s MedWatch program (800-332-1088 to request a form).

Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...

Bausch Health BHC 0.91% Cos., the parent company, raised $630 million in the offering. It had been aiming to raise as much as $840 million and sell the stock at $21 to $24 a share, according to a ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade the company's valuation. Learn more on BHC stock here.

Bausch + Lomb is down 17.9% since the beginning of the year, and at $14.78 per share, it is trading 29.4% below its 52-week high of $20.93 from October 2024.

Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos. Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval. As if ...

Bausch + Lomb Corp. announced June 30 that it will acquire XIIDRA, a treatment for dry eye disease, from Novartis for up to $2.5 billion.

Bausch + Lomb drug Miebo is now FDA approved as a new treatment for dry eye disease. Unlike many products that rewet the eye, Miebo is designed to address one of the factors that leads to dry eyes.

Bausch + Lomb has obtained fully committed financing from J.P. Morgan for the transaction and intends to finance the $1.75 billion upfront cash purchase price with new debt prior to closing.

Shares of Bausch + Lomb Corp. were up 3.1% in premarket trading on Thursday after the eyecare company outperformed earnings and revenue expectations in the second quarter of 2022.